HCW Biologics Key Executives
This section highlights HCW Biologics's key executives, including their titles and compensation details.
Find Contacts at HCW Biologics
(Showing 0 of )
HCW Biologics Earnings
This section highlights HCW Biologics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for HCW Biologics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.57M | $2.84M | $6.72M | $- | $4.10M |
| Cost of Revenue | $1.61M | $2.28M | $4.14M | $543.60K | $- |
| Gross Profit | $959.40K | $560.36K | $2.59M | $-543.60K | $4.10M |
| Gross Profit Ratio | 37.38% | 19.72% | 38.48% | - | 100.00% |
| Research and Development Expenses | $6.39M | $7.68M | $9.34M | $8.17M | $7.26M |
| General and Administrative Expenses | $6.84M | $13.08M | $8.33M | $4.98M | $2.44M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $6.84M | $13.08M | $8.33M | $4.98M | $2.44M |
| Other Expenses | $15.60M | $5.52M | $304.74K | $218.47K | $233.04K |
| Operating Expenses | $28.83M | $26.28M | $17.67M | $13.37M | $9.92M |
| Cost and Expenses | $30.44M | $28.56M | $21.80M | $13.37M | $9.92M |
| Interest Income | $- | $- | $126.66K | $505.37K | $22.32K |
| Interest Expense | $1.16M | $283.04K | $126.66K | $- | $- |
| Depreciation and Amortization | $1.18M | $1.14M | $589.61K | $543.60K | $572.87K |
| EBITDA | $-27.68M | $-23.58M | $-14.18M | $-12.82M | $-5.25M |
| EBITDA Ratio | -1078.43% | -829.62% | -211.01% | - | -128.10% |
| Operating Income | $-29.48M | $-25.72M | $-15.08M | $-13.37M | $-5.82M |
| Operating Income Ratio | -1148.50% | -904.96% | -224.32% | - | -142.07% |
| Total Other Income Expenses Net | $-544.15K | $722.88K | $178.07K | $505.37K | $22.32K |
| Income Before Tax | $-30.02M | $-24.99M | $-14.90M | $-12.86M | $-5.80M |
| Income Before Tax Ratio | -1169.70% | -879.52% | -221.67% | - | -141.53% |
| Income Tax Expense | $- | $- | $-178.07K | $-505.37K | $-22.32K |
| Net Income | $-30.02M | $-24.99M | $-14.72M | $-12.36M | $-5.78M |
| Net Income Ratio | -1169.70% | -879.52% | -219.02% | - | -140.98% |
| EPS | $-0.77 | $-0.70 | $-0.41 | $-0.35 | $-0.16 |
| EPS Diluted | $-0.77 | $-0.70 | $-0.41 | $-0.35 | $-0.16 |
| Weighted Average Shares Outstanding | 38.79M | 35.93M | 35.82M | 35.77M | 36.70M |
| Weighted Average Shares Outstanding Diluted | 38.79M | 35.93M | 35.82M | 35.77M | 36.70M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $394.80K | $426.42K | $618.85K | $1.13M | $1.32M | $853.10K | $622.81K | $41.88K | $1.34M | $1.81M | $454.00K | $3.12M | $- | $- | $- | $- | $4.10M | $- | $- | $- |
| Cost of Revenue | $315.84K | $341.14K | $438.44K | $755.47K | $1.35M | $678.33K | $502.40K | $29.35K | $1.07M | $1.45M | $287.20K | $1.33M | $95.58K | $124.12K | $165.09K | $158.81K | $- | $- | $- | $- |
| Gross Profit | $78.96K | $85.28K | $180.41K | $371.25K | $-21.91K | $174.78K | $120.41K | $12.53K | $268.30K | $361.81K | $166.80K | $1.79M | $-95.58K | $-124.12K | $-165.09K | $-158.81K | $4.10M | $- | $- | $- |
| Gross Profit Ratio | 20.00% | 20.00% | 29.15% | 32.95% | -1.65% | 20.49% | 19.33% | 29.92% | 20.00% | 20.00% | 36.74% | 57.40% | - | - | - | - | 100.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $1.05M | $1.19M | $2.03M | $1.95M | $2.14M | $1.67M | $1.62M | $2.26M | $2.93M | $2.65M | $1.97M | $1.79M | $1.48M | $2.69M | $1.67M | $2.33M | $1.41M | $2.10M | $2.07M | $1.68M |
| General and Administrative Expenses | $1.44M | $1.57M | $1.59M | $5.92M | $3.56M | $3.52M | $2.95M | $3.05M | $3.01M | $1.70M | $1.69M | $1.84M | $1.58M | $1.36M | $1.02M | $1.02M | $569.08K | $553.19K | $654.55K | $659.18K |
| Selling and Marketing Expenses | $- | $-20.21K | $-66.61K | $-67.08K | $5.05M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $1.44M | $2.52M | $11.92M | $5.92M | $8.61M | $3.52M | $2.95M | $3.05M | $3.01M | $1.70M | $1.69M | $1.84M | $1.58M | $1.36M | $1.02M | $1.02M | $569.08K | $553.19K | $654.55K | $659.18K |
| Other Expenses | $750.76K | $69.37K | $1.37M | $25.60K | $86.24K | $234.75K | $301.62K | $69.21K | $-84.48K | $- | $16.94K | $35.60K | $-162.66K | $44.82K | $61.08K | $66.64K | $60.23K | $56.75K | $56.67K | $59.38K |
| Operating Expenses | $3.24M | $3.78M | $15.32M | $7.86M | $10.75M | $5.25M | $4.63M | $5.37M | $5.94M | $4.38M | $3.68M | $3.67M | $3.11M | $4.09M | $2.75M | $3.41M | $2.04M | $2.71M | $2.78M | $2.40M |
| Cost and Expenses | $3.55M | $4.12M | $15.75M | $8.62M | $12.09M | $5.93M | $5.13M | $5.40M | $7.01M | $5.83M | $3.97M | $5.00M | $3.11M | $4.09M | $2.75M | $3.41M | $2.04M | $2.71M | $2.78M | $2.40M |
| Interest Income | $- | $- | $- | $- | $- | $- | $95.51K | $- | $248.50K | $- | $516 | $- | $- | $- | $631 | $568.18K | $- | $- | $1.52K | $21.48K |
| Interest Expense | $775.41K | $223.36K | $159.67K | $- | $- | $95.51K | $95.51K | $93.44K | $21.20K | $- | $516 | $176.40K | $- | $2.54K | $- | $568.18K | $- | $374 | $- | $21.48K |
| Depreciation and Amortization | $682.51K | $128.45K | $129.93K | $243.50K | $274.55K | $277.45K | $284.33K | $298.85K | $132.91K | $164.33K | $149.58K | $142.78K | $95.58K | $124.12K | $165.09K | $158.81K | $163.69K | $126.21K | $158.11K | $147.90K |
| EBITDA | $-1.92M | $-3.55M | $-14.99M | $-7.22M | $-10.41M | $-4.57M | $-3.92M | $-4.68M | $-5.29M | $-3.75M | $-3.36M | $-1.91M | $-3.02M | $-3.97M | $-2.60M | $-3.25M | $2.20M | $-2.58M | $-2.62M | $-2.25M |
| EBITDA Ratio | -485.14% | -832.62% | -2422.32% | -641.21% | -785.95% | -535.19% | -630.14% | -11170.17% | -394.02% | -207.29% | -740.30% | -61.41% | - | - | - | - | 53.70% | - | - | - |
| Operating Income | $-3.16M | $-3.69M | $-15.14M | $-7.49M | $-10.77M | $-5.08M | $-4.51M | $-5.36M | $-5.67M | $-4.02M | $-3.51M | $-1.88M | $-3.11M | $-4.09M | $-2.75M | $-3.41M | $2.06M | $-2.71M | $-2.78M | $-2.40M |
| Operating Income Ratio | -800.34% | -865.39% | -2445.81% | -665.09% | -813.31% | -595.23% | -724.22% | -12798.92% | -422.45% | -222.20% | -773.36% | -60.33% | - | - | - | - | 50.27% | - | - | - |
| Total Other Income Expenses Net | $-213.51K | $-212.05K | $-144.18K | $25.60K | $87.66K | $139.24K | $206.10K | $289.88K | $248.50K | $105.46K | $516 | $-176.40K | $-60.90K | $-2.54K | $631 | $568.18K | $-303 | $-374 | $1.52K | $21.48K |
| Income Before Tax | $-3.37M | $-3.90M | $-15.28M | $-7.47M | $-10.68M | $-4.94M | $-4.30M | $-5.07M | $-5.42M | $-3.91M | $-3.51M | $-2.06M | $-3.17M | $-4.09M | $-2.75M | $-2.84M | $2.06M | $-2.71M | $-2.78M | $-2.38M |
| Income Before Tax Ratio | -854.42% | -915.12% | -2469.11% | -662.82% | -806.69% | -578.90% | -691.13% | -12106.79% | -403.93% | -216.37% | -773.25% | -65.99% | - | - | - | - | 50.27% | - | - | - |
| Income Tax Expense | $- | $- | $- | $-1 | $-530.95K | $330.27K | $397.13K | $- | $-72.61K | $- | $-516 | $176.40K | $1 | $- | $- | $- | $- | $- | $- | $- |
| Net Income | $-3.37M | $-3.90M | $-15.28M | $-7.47M | $-10.68M | $-4.94M | $-4.30M | $-5.07M | $-5.35M | $-3.91M | $-3.51M | $-2.23M | $-3.17M | $-4.09M | $-2.75M | $-2.84M | $2.06M | $-2.71M | $-2.78M | $-2.38M |
| Net Income Ratio | -854.42% | -915.12% | -2469.11% | -662.82% | -806.69% | -578.90% | -691.13% | -12106.79% | -398.51% | -216.37% | -773.14% | -71.65% | - | - | - | - | 50.27% | - | - | - |
| EPS | $-0.08 | $-0.10 | $-0.40 | $-0.20 | $-0.30 | $-0.14 | $-0.12 | $-0.14 | $-0.15 | $-0.11 | $-0.10 | $-0.06 | $-0.11 | $-0.14 | $-0.08 | $-0.08 | $0.07 | $-0.09 | $-0.10 | $-0.08 |
| EPS Diluted | $-0.08 | $-0.10 | $-0.40 | $-0.20 | $-0.30 | $-0.14 | $-0.12 | $-0.14 | $-0.15 | $-0.11 | $-0.10 | $-0.06 | $-0.11 | $-0.14 | $-0.08 | $-0.08 | $0.07 | $-0.09 | $-0.10 | $-0.08 |
| Weighted Average Shares Outstanding | 42.30M | 37.82M | 37.82M | 37.22M | 36.00M | 35.93M | 35.91M | 35.88M | 35.86M | 35.84M | 35.81M | 35.78M | 29.57M | 29.57M | 34.25M | 34.25M | 28.61M | 28.61M | 28.61M | 28.61M |
| Weighted Average Shares Outstanding Diluted | 42.30M | 37.82M | 37.82M | 37.22M | 36.00M | 35.93M | 35.91M | 35.88M | 35.86M | 35.84M | 35.81M | 35.78M | 29.57M | 29.57M | 34.25M | 34.25M | 28.61M | 28.61M | 28.61M | 28.61M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.67M | $3.60M | $22.33M | $11.73M | $8.46M |
| Short Term Investments | $- | $- | $9.74M | $24.98M | $- |
| Cash and Short Term Investments | $4.67M | $3.60M | $32.06M | $36.71M | $8.46M |
| Net Receivables | $582.20K | $1.54M | $417.69K | $133.00K | $2.50M |
| Inventory | $- | $- | $1.39M | $2.20M | $538.31K |
| Other Current Assets | $441.71K | $1.27M | $1.59M | $3.63M | $1.19M |
| Total Current Assets | $5.70M | $6.40M | $34.07M | $40.48M | $12.15M |
| Property Plant Equipment Net | $22.91M | $20.45M | $10.80M | $1.12M | $1.62M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $1.60M | $1.60M | $1.60M | $11.52M | $1.60M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $28.48K | $56.54K | $333.88K | $393.32K | $34.24K |
| Total Non-Current Assets | $24.54M | $22.11M | $12.74M | $13.03M | $3.25M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $30.24M | $28.51M | $46.81M | $53.51M | $15.40M |
| Account Payables | $22.33M | $6.17M | $1.23M | $223.66K | $155.34K |
| Short Term Debt | $6.31M | $- | $- | $- | $567.31K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $1.80M | $-567.31K |
| Other Current Liabilities | $981.94K | $2.58M | $1.73M | $2.10M | $278.43K |
| Total Current Liabilities | $29.63M | $8.75M | $2.96M | $2.32M | $1.00M |
| Long Term Debt | $- | $6.30M | $6.41M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $7.38M | $- | $14.28K | $- | $- |
| Total Non-Current Liabilities | $7.38M | $6.30M | $6.42M | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $37.01M | $15.05M | $9.38M | $2.32M | $1.00M |
| Preferred Stock | $- | $- | $- | $53.51M | $31.12M |
| Common Stock | $4.45K | $3.60K | $3.59K | $3.58K | $480 |
| Retained Earnings | $-100.56M | $-70.53M | $-45.54M | $-30.64M | $-16.72M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-53.51M | $-1.12K |
| Other Total Stockholders Equity | $93.78M | $83.99M | $82.96M | $28.31M | $- |
| Total Stockholders Equity | $-6.77M | $13.46M | $37.43M | $51.19M | $14.40M |
| Total Equity | $-6.77M | $13.46M | $37.43M | $51.19M | $14.40M |
| Total Liabilities and Stockholders Equity | $30.24M | $28.51M | $46.81M | $53.51M | $15.40M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $30.24M | $28.51M | $46.81M | $53.51M | $15.40M |
| Total Investments | $1.60M | $1.60M | $11.34M | $36.51M | $1.60M |
| Total Debt | $6.31M | $6.30M | $6.41M | $- | $567.31K |
| Net Debt | $1.64M | $2.71M | $-15.92M | $-11.73M | $-7.89M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $4.67M | $998.22K | $1.16M | $4.08M | $3.60M | $11.22M | $7.45M | $18.39M | $22.33M | $26.22M | $15.42M | $18.12M | $11.73M | $15.13M | $5.05M | $6.86M | $8.46M | $-7.36M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $9.96M | $9.85M | $9.74M | $- | $16.99M | $16.97M | $24.98M | $24.99M | $- | $- | $- | $14.71M |
| Cash and Short Term Investments | $4.67M | $998.22K | $1.16M | $4.08M | $3.60M | $11.22M | $17.41M | $28.24M | $32.06M | $26.22M | $32.41M | $35.09M | $36.71M | $40.11M | $5.05M | $6.86M | $8.46M | $7.36M |
| Net Receivables | $582.20K | $651.84K | $654.97K | $1.15M | $1.54M | $710.08K | $707.21K | $252.73K | $417.69K | $355.56K | $346.93K | $553.01K | $133.00K | $70.00K | $50.00K | $1.30M | $2.50M | $- |
| Inventory | $- | $- | $- | $1 | $- | $1.74M | $1.36M | $- | $1.39M | $1 | $1.40M | $2.02M | $2.20M | $1.99M | $4.05M | $783.32K | $538.31K | $- |
| Other Current Assets | $441.71K | $444.29K | $569.52K | $970.69K | $1.27M | $1.92M | $1.68M | $1.45M | $1.59M | $2.13M | $1.87M | $2.27M | $3.63M | $3.37M | $4.95M | $1.64M | $1.19M | $- |
| Total Current Assets | $5.70M | $2.09M | $2.39M | $6.21M | $6.40M | $13.85M | $19.80M | $29.94M | $34.07M | $28.71M | $34.63M | $37.91M | $40.48M | $43.56M | $10.05M | $9.80M | $12.15M | $7.36M |
| Property Plant Equipment Net | $22.91M | $22.83M | $22.81M | $22.59M | $20.45M | $14.78M | $12.62M | $11.74M | $10.80M | $10.96M | $913.73K | $1.01M | $1.12M | $1.27M | $1.39M | $1.53M | $1.62M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $11.27M | $11.30M | $11.35M | $11.52M | $11.58M | $1.60M | $1.60M | $1.60M | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $28.48K | $28.48K | $28.48K | $28.48K | $56.54K | $5.39M | $5.46M | $253.14K | $333.88K | $419.03K | $563.51K | $686.41K | $393.32K | $- | $- | $- | $34.24K | $-7.36M |
| Total Non-Current Assets | $24.54M | $24.46M | $24.43M | $24.22M | $22.11M | $21.77M | $19.68M | $13.59M | $12.74M | $22.65M | $12.78M | $13.05M | $13.03M | $12.85M | $2.99M | $3.13M | $3.25M | $-7.36M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $30.24M | $26.56M | $26.82M | $30.43M | $28.51M | $35.62M | $39.48M | $43.53M | $46.81M | $51.35M | $47.41M | $50.96M | $53.51M | $56.41M | $13.03M | $12.93M | $15.40M | $- |
| Account Payables | $22.33M | $22.67M | $16.88M | $10.49M | $6.17M | $3.15M | $2.12M | $1.16M | $1.23M | $1.41M | $296.21K | $743.12K | $223.66K | $637.19K | $996.88K | $323.50K | $155.34K | $- |
| Short Term Debt | $6.31M | $6.34M | $124.00K | $- | $28.50K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $-122.15K | $- | $-117.68K | $-97.10K | $- | $- | $- | $- | $- | $1.80M | $- | $- | $- | $-567.31K | $- |
| Other Current Liabilities | $981.94K | $1.06M | $6.22M | $2.92M | $2.55M | $2.26M | $2.42M | $3.36M | $1.73M | $882.77K | $848.34K | $674.30K | $2.10M | $1.76M | $3.17M | $1.02M | $845.74K | $- |
| Total Current Liabilities | $29.63M | $30.06M | $23.22M | $13.41M | $8.75M | $5.42M | $4.54M | $4.52M | $2.96M | $2.29M | $1.14M | $1.42M | $2.32M | $2.39M | $4.17M | $1.35M | $1.00M | $- |
| Long Term Debt | $7.38M | $6.46M | $9.90M | $8.27M | $6.30M | $6.33M | $6.36M | $6.39M | $6.41M | $6.45M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $7.48K | $14.28K | $56.68K | $98.45K | $139.60K | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $7.38M | $6.46M | $9.90M | $8.27M | $6.30M | $6.33M | $6.36M | $6.39M | $6.42M | $6.50M | $98.45K | $139.60K | $223.66K | $- | $- | $- | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-223.66K | $- | $- | $- | $- | $- |
| Total Liabilities | $37.01M | $36.53M | $33.12M | $21.69M | $15.05M | $11.75M | $10.90M | $10.92M | $9.38M | $8.80M | $1.24M | $1.56M | $2.32M | $2.39M | $4.17M | $1.35M | $1.00M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $56.41M | $32.10M | $31.61M | $31.12M | $18.68M |
| Common Stock | $4.45K | $3.78K | $3.78K | $3.78K | $3.60K | $3.59K | $3.59K | $3.59K | $3.59K | $3.58K | $3.58K | $3.58K | $3.58K | $3.57K | $496 | $488 | $480 | $- |
| Retained Earnings | $-100.56M | $-97.18M | $-93.28M | $-78.00M | $-70.53M | $-59.85M | $-54.91M | $-50.61M | $-45.54M | $-40.12M | $-36.21M | $-32.69M | $-30.64M | $-27.46M | $-23.24M | $-20.03M | $-16.72M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $0 | $- | $- | $- | $0 | $- | $0 | $0 | $-56.41M | $-23.24M | $-1.14K | $- | $-9.68M |
| Other Total Stockholders Equity | $93.78M | $87.21M | $86.98M | $86.74M | $83.99M | $83.72M | $83.50M | $83.22M | $82.96M | $82.67M | $82.37M | $82.09M | $81.83M | $81.47M | $- | $- | $- | $- |
| Total Stockholders Equity | $-6.77M | $-9.97M | $-6.30M | $8.74M | $13.46M | $23.87M | $28.59M | $32.62M | $37.43M | $42.56M | $46.17M | $49.40M | $51.19M | $54.01M | $8.86M | $11.58M | $14.40M | $9.00M |
| Total Equity | $-6.77M | $-9.97M | $-6.30M | $8.74M | $13.46M | $23.87M | $28.59M | $32.62M | $37.43M | $42.56M | $46.17M | $49.40M | $51.19M | $54.01M | $8.86M | $11.58M | $14.40M | $9.00M |
| Total Liabilities and Stockholders Equity | $30.24M | $26.56M | $26.82M | $30.43M | $28.51M | $35.62M | $39.48M | $43.53M | $46.81M | $51.35M | $47.41M | $50.96M | $53.51M | $56.41M | $13.03M | $12.93M | $15.40M | $9.00M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $30.24M | $26.56M | $26.82M | $30.43M | $28.51M | $35.62M | $39.48M | $43.53M | $46.81M | $51.35M | $47.41M | $50.96M | $53.51M | $56.41M | $13.03M | $12.93M | $15.40M | $9.00M |
| Total Investments | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $1.60M | $11.56M | $11.45M | $11.34M | $11.27M | $28.30M | $28.32M | $36.51M | $36.57M | $1.60M | $1.60M | $1.60M | $14.71M |
| Total Debt | $13.69M | $12.80M | $10.02M | $8.27M | $6.45M | $6.33M | $6.36M | $6.39M | $6.41M | $6.45M | $98.45K | $139.60K | $- | $- | $- | $- | $567.31K | $- |
| Net Debt | $9.02M | $11.81M | $8.86M | $4.19M | $2.86M | $-4.89M | $-1.09M | $-12.00M | $-15.92M | $-19.78M | $-15.32M | $-17.98M | $-11.73M | $-15.13M | $-5.05M | $-6.86M | $-7.89M | $7.36M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-30.02M | $-24.99M | $-14.90M | $-12.86M | $-5.80M |
| Depreciation and Amortization | $1.18M | $1.14M | $717.85K | $543.60K | $595.91K |
| Deferred Income Tax | $- | $- | $- | $-501.48K | $-4.32M |
| Stock Based Compensation | $1.01M | $1.00M | $1.12M | $360.98K | $21.88K |
| Change in Working Capital | $13.60M | $-4.64M | $2.49M | $1.46M | $-5.25M |
| Accounts Receivables | $953.56K | $-1.12M | $-284.69K | $2.37M | $-2.50M |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $11.87M | $1.62M | $418.21K | $1.89M | $-628.65K |
| Other Working Capital | $775.08K | $-5.14M | $2.35M | $-2.80M | $-2.12M |
| Other Non Cash Items | $-418 | $4.98M | $188.46K | $28.26K | $4.32M |
| Net Cash Provided by Operating Activities | $-14.23M | $-22.51M | $-10.39M | $-10.98M | $-10.43M |
| Investments in Property Plant and Equipment | $-261.62K | $-6.20M | $-10.28M | $-47.26K | $-186.68K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $-34.97M | $- |
| Sales Maturities of Investments | $- | $10.00M | $24.98M | $- | $- |
| Other Investing Activities | $- | $- | $24.98M | $-34.97M | $- |
| Net Cash Used for Investing Activities | $-261.62K | $3.80M | $14.71M | $-35.02M | $-186.68K |
| Debt Repayment | $6.79M | $-38.27K | $6.45M | $- | $563.59K |
| Common Stock Issued | $6.46M | $23.74K | $15.78K | $56.03M | $9.90K |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $-2.82M | $- |
| Other Financing Activities | $2.32M | $- | $-190.55K | $-6.76M | $22.30M |
| Net Cash Used Provided by Financing Activities | $15.57M | $-14.53K | $6.27M | $49.27M | $11.72M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.08M | $-18.73M | $10.60M | $3.27M | $1.10M |
| Cash at End of Period | $4.67M | $3.60M | $22.33M | $11.73M | $8.46M |
| Cash at Beginning of Period | $3.60M | $22.33M | $11.73M | $8.46M | $7.36M |
| Operating Cash Flow | $-14.23M | $-22.51M | $-10.39M | $-10.98M | $-10.43M |
| Capital Expenditure | $-261.62K | $-6.20M | $-10.28M | $-47.26K | $-186.68K |
| Free Cash Flow | $-14.49M | $-28.72M | $-20.66M | $-11.02M | $-10.62M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-3.37M | $-3.90M | $-15.28M | $-7.47M | $-10.68M | $-4.94M | $-4.30M | $-5.07M | $-5.42M | $-3.91M | $-3.51M | $-2.06M | $-3.17M | $-4.09M | $-2.75M | $-2.84M | $2.06M | $-2.71M | $-2.78M | $-2.38M |
| Depreciation and Amortization | $682.51K | $128.45K | $129.93K | $243.50K | $274.55K | $277.45K | $284.33K | $298.85K | $261.16K | $164.33K | $149.58K | $142.78K | $95.58K | $124.12K | $165.09K | $158.81K | $163.69K | $126.21K | $158.11K | $147.90K |
| Deferred Income Tax | $- | $- | $- | $- | $-409.50K | $-40.63K | $-110.94K | $- | $- | $- | $- | $- | $-1.36M | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $292.07K | $232.43K | $239.82K | $244.69K | $261.27K | $219.85K | $263.42K | $259.21K | $286.19K | $302.32K | $271.33K | $260.35K | $360.98K | $1.66K | $- | $- | $21.88K | $- | $- | $- |
| Change in Working Capital | $-436.19K | $614.93K | $10.05M | $3.38M | $1.00M | $-1.11M | $-5.52M | $986.71K | $1.15M | $1.09M | $374.97K | $-123.42K | $-753.84K | $-1.15M | $1.59M | $1.76M | $-5.78M | $-166.74K | $457.19K | $246.16K |
| Accounts Receivables | $69.64K | $3.13K | $248.91K | $631.87K | $-825.68K | $-2.87K | $-454.48K | $164.97K | $-62.14K | $-8.62K | $206.07K | $-420.01K | $-63.00K | $-20.00K | $1.25M | $1.20M | $-2.50M | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.88M | $-42.78M | $-6.29M | $- | $- | $- | $- | $- |
| Accounts Payables | $-508.40K | $486.56K | $9.40M | $2.50M | $1.23M | $-820.12K | $494.25K | $718.67K | $621.19K | $1.14M | $-276.64K | $-1.07M | $-72.91K | $489.76K | $757.91K | $713.05K | $-1.15M | $28.74K | $430.36K | $57.92K |
| Other Working Capital | $2.58K | $125.24K | $401.17K | $246.10K | $599.67K | $-283.69K | $-5.56M | $103.07K | $589.53K | $-48.17K | $445.54K | $1.37M | $-2.50M | $41.16M | $5.88M | $-150.36K | $-2.14M | $-195.49K | $26.83K | $188.25K |
| Other Non Cash Items | $- | $- | $- | $-2.40M | $5.66M | $-627 | $-627 | $-112.29K | $-66.55K | $627 | $24.84K | $185.33K | $1.46M | $-221.53K | $-1.68M | $-567.31K | $21.88K | $28.74K | $430.36K | $57.92K |
| Net Cash Provided by Operating Activities | $-2.83M | $-2.93M | $-4.86M | $-3.60M | $-3.89M | $-5.59M | $-9.39M | $-3.64M | $-3.79M | $-2.31M | $-2.69M | $-1.59M | $-3.38M | $-5.12M | $-990.44K | $-1.49M | $-3.54M | $-2.75M | $-2.16M | $-1.98M |
| Investments in Property Plant and Equipment | $-113.41K | $-37.06K | $18.57K | $-129.71K | $-3.72M | $-630.05K | $-1.56M | $-300.38K | $-68.69K | $-10.17M | $-12.91K | $-23.55K | $-19.85K | $-4.13K | $- | $-23.28K | $-36.39K | $-105.22K | $55.78K | $-100.86K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.05K | $-34.97M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $10.00M | $- | $- | $8.00M | $16.98M | $- | $8.00M | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $10.00M | $- | $- | $-8.00M | $16.98M | $- | $8.00M | $-4.05K | $-34.97M | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-113.41K | $-37.06K | $18.57K | $-129.71K | $-3.72M | $9.37M | $-1.56M | $-300.38K | $-68.69K | $6.81M | $-12.91K | $7.98M | $-23.90K | $-34.97M | $- | $-23.28K | $-36.39K | $-105.22K | $55.78K | $-100.86K |
| Debt Repayment | $343.99K | $2.80M | $1.92M | $1.72M | $-29.29K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $3.96M | $- | $- | $2.50M | $14.04K | $84 | $7.71K | $1.90K | $5.83K | $1.67K | $6.00K | $2.27K | $6.10K | $56.00M | $9.46K | $13.38K | $6.78K | $813 | $2.31K | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-2.82M | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $2.32M | $- | $- | $2.50M | $- | $-8.98K | $- | $- | $-45.68K | $6.30M | $- | $- | $- | $-5.84M | $-824.31K | $-100.00K | $5.54M | $6.17M | $- | $- |
| Net Cash Used Provided by Financing Activities | $6.62M | $2.80M | $1.92M | $4.22M | $-15.25K | $-8.90K | $7.71K | $1.90K | $-39.85K | $6.30M | $6.00K | $2.27K | $6.10K | $50.16M | $-814.85K | $-86.61K | $5.55M | $6.17M | $2.31K | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-11.01M | $- | $11.01M | $- | $- | $- | $- | $- | $4.91M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $3.68M | $-163.09K | $-2.92M | $488.97K | $-7.63M | $3.77M | $-10.94M | $-3.94M | $-3.90M | $10.80M | $-2.70M | $6.39M | $-3.39M | $10.07M | $-1.81M | $-1.60M | $1.97M | $3.31M | $-2.11M | $-2.08M |
| Cash at End of Period | $4.67M | $998.22K | $1.16M | $4.08M | $3.60M | $11.22M | $7.45M | $18.39M | $22.33M | $26.22M | $15.42M | $18.12M | $11.73M | $15.13M | $5.05M | $6.86M | $8.46M | $6.48M | $3.17M | $5.27M |
| Cash at Beginning of Period | $998.22K | $1.16M | $4.08M | $3.60M | $11.22M | $7.45M | $18.39M | $22.33M | $26.22M | $15.42M | $18.12M | $11.73M | $15.13M | $5.05M | $6.86M | $8.46M | $6.48M | $3.17M | $5.27M | $7.36M |
| Operating Cash Flow | $-2.83M | $-2.93M | $-4.86M | $-3.60M | $-3.89M | $-5.59M | $-9.39M | $-3.64M | $-3.79M | $-2.31M | $-2.69M | $-1.59M | $-3.38M | $-5.12M | $-990.44K | $-1.49M | $-3.54M | $-2.75M | $-2.16M | $-1.98M |
| Capital Expenditure | $-113.41K | $-37.06K | $18.57K | $-129.71K | $-3.72M | $-630.05K | $-1.56M | $-300.38K | $-68.69K | $-10.17M | $-12.91K | $-23.55K | $-19.85K | $-4.13K | $- | $-23.28K | $-36.39K | $-105.22K | $55.78K | $-100.86K |
| Free Cash Flow | $-2.95M | $-2.96M | $-4.84M | $-3.73M | $-7.61M | $-6.22M | $-10.95M | $-3.94M | $-3.86M | $-12.48M | $-2.70M | $-1.62M | $-3.40M | $-5.12M | $-990.44K | $-1.51M | $-3.57M | $-2.85M | $-2.11M | $-2.08M |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
$7.52
Stock Price
$8.45M
Market Cap
36
Employees
Miramar, FL
Location
Revenue (FY 2024)
$2.57M
-9.7% YoY
Net Income (FY 2024)
$-30.02M
-20.1% YoY
EPS (FY 2024)
$-0.77
-10.0% YoY
Free Cash Flow (FY 2024)
$-14.49M
49.5% YoY
Profitability
Gross Margin
37.4%
Net Margin
-1169.7%
ROE
443.5%
ROA
-99.3%
Valuation
P/E Ratio
-23.05
P/S Ratio
269.62
EV/EBITDA
-25.06
Market Cap
$8.45M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-14.23M
36.8% YoY
Free Cash Flow
$-14.49M
49.5% YoY
Balance Sheet Summary
Total Assets
$30.24M
6.0% YoY
Total Debt
$6.31M
0.2% YoY
Shareholder Equity
$-6.77M
-146.6% YoY
Dividend Overview
No Dividend Data
HCW Biologics Inc. doesn't currently pay dividends.
HCW Biologics Dividends
Explore HCW Biologics's dividend history, including dividend yield, payout ratio, and historical payments.
HCW Biologics News
Read the latest news about HCW Biologics, including recent articles, headlines, and updates.
HCW Biologics Announces 1-for-40 Reverse Stock Split
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company's common stock, par value $0.0001 (“Common Stock”), which will be effective at 12:01 a.m. Eastern Time on April 11, 2025. The Company's Common Stock will be traded on The Nasdaq Capital Market on a reverse split-adjusted basis beginning on April 11, 2025, under the Company's existing trading symbol “HCWB.”
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2024.
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported that, on March 3, 2025, the Nasdaq Hearings Panel (the “Panel”) of The Nasdaq Stock Market LLC (“Nasdaq” or the “Exchange”) granted the Company an extension in which to regain compliance with all continued listing rules of The Nasdaq Capital Market.
HCW Biologics Granted FDA Clearance to Evaluate One of the Company's Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, today announced that it has received clearance of its Investigational New Drug Application (“IND”) from the U.S. Food and Drug Administration (“FDA”) to initiate a first-in-human Phase 1 dose escalation clinical trial to evaluate one of its lead drug candidates, HCW9302, in patients with moderate-to-severe alopecia areata, a common autoimmune disease in humans that currently has no curative FDA approved treatments.
HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025
MIRAMAR, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic inflammation and disease, announced today that Hing C.
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff (“Staff”) that it had failed to re-gain compliance for continued listing requirements of the Nasdaq Global Markets.
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced above market under Nasdaq rules.
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales MIRAMAR, Fla., Nov. 18, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd.
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
MIRAMAR, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2024.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
This release has made a correction to a release issued under the same headline on August 14, 2024, by HCW Biologics, Inc. (NASDAQ: HCWB), to show the amount included in the condensed interim balance sheet for Cash and cash equivalents as of December 31, 2023 as $3,595,101, not $95,101 as previously stated. The full text of the corrected release is as follows: MIRAMAR, Fla.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
MIRAMAR, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2024.
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
MIRAMAR, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its first quarter ended March 31, 2024.
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
MIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023.
Investigator Sponsor of HCW Biologics' Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
Showed HCW9218 clinical safety and tumor response endpoints for 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced results from a preliminary human data readout from an ongoing Phase 1 clinical trial sponsored by the University of Minnesota to evaluate HCW9218, the lead drug candidate of HCW Biologics, in patients with solid tumors who failed at least two prior lines of therapy.
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
MIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023.
Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers
The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex designed to drive anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities.
HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo
HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced senescence (TIS).
Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps
Three penny stocks that could be worth watching in the second half of October The post Making a Penny Stocks Watchlist? Don't Forget These 3 Small-Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
HCW Biologics' Article Published in Cancer Immunology Research Validates Novel Tissue Factor Scaffold Fusion Protein (TOBI™) Discovery Platform
TOBI™ Discovery Platform Creates GMP-Scale Heteromeric Fusion Protein Complexes (HFPCs) That Solve Issues with Multi-Signal Receptor Engagement on Immune Cells
HCW Biologics Reports Second Quarter Financial Results and Recent Business Highlights
MIRAMAR, Fla., Aug. 13, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), an innovative, biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2021.
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
MIRAMAR, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (NASDAQ:HCWB) (the "Company"), an innovative preclinical stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation and age-related diseases, today announced the closing of its previously announced underwritten initial public offering of 7,000,000 shares of common stock at a public offering price of $8.00 per share for gross proceeds of $56.0 million, prior to deducting underwriting discounts, commissions, and other offering expenses. All of the shares of common stock were offered by the Company. The shares began trading on the Nasdaq Global Market on July 20, 2021, under the ticker symbol “HCWB.” In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,050,000 shares at the public offering price less the underwriting discounts and commissions.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for HCWB.